PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.10%
Revenue growth 1.25-1.5x AVGO's 6.32%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
15.50%
Gross profit growth above 1.5x AVGO's 4.96%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
17.77%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
17.77%
Operating income growth above 1.5x AVGO's 1.00%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
53.51%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
36.00%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
51.11%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
8.15%
Share count expansion well above AVGO's 0.15%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.06%
Diluted share count expanding well above AVGO's 0.70%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-20.37%
Negative OCF growth while AVGO is at 9.32%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-40.62%
Negative FCF growth while AVGO is at 9.56%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
439.39%
Similar 10Y revenue/share CAGR to AVGO's 416.86%. Walter Schloss might see both firms benefiting from the same long-term demand.
64.09%
5Y revenue/share CAGR under 50% of AVGO's 134.28%. Michael Burry would suspect a significant competitive gap or product weakness.
57.73%
3Y revenue/share CAGR similar to AVGO's 62.33%. Walter Schloss would assume both companies experience comparable short-term cycles.
3325.64%
10Y OCF/share CAGR above 1.5x AVGO's 580.47%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
350.56%
5Y OCF/share CAGR above 1.5x AVGO's 92.77%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
20671.08%
3Y OCF/share CAGR above 1.5x AVGO's 39.51%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
782.52%
Net income/share CAGR at 75-90% of AVGO's 869.72%. Bill Ackman would press for strategic moves to boost long-term earnings.
108.79%
Below 50% of AVGO's 414.43%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
473.30%
3Y net income/share CAGR above 1.5x AVGO's 16.00%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1169.28%
10Y equity/share CAGR 1.25-1.5x AVGO's 862.23%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
144.32%
5Y equity/share CAGR at 75-90% of AVGO's 165.61%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
61.77%
Below 50% of AVGO's 201.93%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.08%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-5.05%
Inventory is declining while AVGO stands at 8.08%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
5.69%
Asset growth above 1.5x AVGO's 0.60%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
0.54%
Under 50% of AVGO's 5.15%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-100.00%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
15.31%
R&D growth drastically higher vs. AVGO's 13.26%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
12.33%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.